CTLA4 and pancreatic neoplasm: Similarly, combining GM-CSF with CTLA-4 blocking mAb ipilimumab improved tumor antigen-specific T cell responses in prostate (197) and pancreatic cancer (198) in comparison to either GM-CSF or ipilimumab alone.